BidaskClub cut shares of AVEO Pharmaceuticals (NASDAQ:AVEO) from a sell rating to a strong sell rating in a report issued on Tuesday morning.
A number of other brokerages have also recently commented on AVEO. started coverage on AVEO Pharmaceuticals in a research report on Wednesday, November 15th. They issued a buy rating and a $5.00 price target for the company. B. Riley started coverage on AVEO Pharmaceuticals in a research report on Monday, November 13th. They issued a buy rating and a $5.00 price target for the company. Zacks Investment Research cut AVEO Pharmaceuticals from a hold rating to a sell rating in a research report on Wednesday, December 6th. Finally, Seaport Global Securities restated a buy rating on shares of AVEO Pharmaceuticals in a research report on Friday, October 6th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and a consensus target price of $4.05.
Shares of AVEO Pharmaceuticals (NASDAQ AVEO) opened at $3.10 on Tuesday. The company has a quick ratio of 2.33, a current ratio of 2.33 and a debt-to-equity ratio of -0.32. AVEO Pharmaceuticals has a 1 year low of $0.50 and a 1 year high of $4.24.
Several large investors have recently added to or reduced their stakes in the stock. RA Capital Management LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter worth about $18,727,000. Vanguard Group Inc. grew its position in shares of AVEO Pharmaceuticals by 48.6% during the second quarter. Vanguard Group Inc. now owns 3,551,360 shares of the biopharmaceutical company’s stock worth $7,884,000 after purchasing an additional 1,162,232 shares in the last quarter. EAM Investors LLC purchased a new stake in shares of AVEO Pharmaceuticals during the second quarter worth about $1,979,000. Essex Investment Management Co. LLC purchased a new stake in shares of AVEO Pharmaceuticals during the third quarter worth about $550,000. Finally, OxFORD Asset Management LLP purchased a new stake in shares of AVEO Pharmaceuticals during the third quarter worth about $228,000. Hedge funds and other institutional investors own 50.91% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “BidaskClub Downgrades AVEO Pharmaceuticals (AVEO) to Strong Sell” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/13/bidaskclub-downgrades-aveo-pharmaceuticals-aveo-to-strong-sell.html.
AVEO Pharmaceuticals Company Profile
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.